Individuals with asthma and chronic obstructive pulmonary disease (COPD) were more vulnerable than healthy controls to ...

Among patients with COPD, those receiving 6-week nicotinamide riboside, “a B3-like vitamin,” had significantly decreased lung ...

“This could influence treatment decisions ... it is known that obesity affects lung function and does make obstructive lung disease such as COPD and asthma much more difficult to control ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments ... that obesity affects lung function and does make obstructive lung disease such as COPD and asthma much more difficult ...

and asthma, today announced five poster presentations and an oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego ...

St. Vincent’s Riverside is now offering a breakthrough treatment for patients diagnosed with chronic pulmonary obstructive ...

Respiratory diseases are a challenging problem to treat. Inhalable medicines are a promising solution that depends on the ...

Feb. 3, 2025 — Long-term exposure to PM2.5, PM10, NO2 and ozone (O3) air pollution is associated with more hospital admissions for lower respiratory tract infections in ... Researchers Identify ...

"If we can target these molecules in human patients, they might be able to develop long-lasting tolerance to allergens." ...

cutting the rate of moderate to severe exacerbations – sudden worsening of COPD symptoms – by 42% over 24 weeks. Ensifentrine also achieved significant improvements in key measures of lung ...

AstraZeneca will pay the Barcelona-headquartered pharma company $875 million to buy Eklira, its COPD and asthma treatment, plus a number of other clinical and pre-clinical candidates. The deal ...

12 Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada Correspondence to Dr Wan C Tan, UBC James Hogg Research Centre, Providence Heart+Lung ... of COPD in never-smokers ...